CellTrans
CellTrans is dedicated to developing, manufacturing, and commercializing FDA-approved cell therapies and bioengineered technologies for treating diabetes and endocrine disorders. Their mission is to pioneer cell therapies for clinical application and improve human health through functional cures via bioengineered cell transplantation. The company originated from Dr. José Oberholzer’s research group at the University of Illinois and focuses on bringing cell-based therapies, including islets, encapsulated islets, and stem cells, into clinical use to combat diabetes and related conditions.
Industries
Nr. of Employees
small (1-50)
CellTrans
Products
Clinical-grade allogeneic pancreatic islet cellular suspension
cGMP-manufactured allogeneic pancreatic islet cellular suspension produced for clinical transplantation and regulated clinical use.
Lantidra (donislecel-jujn) Allogeneic Pancreatic Islet Cellular Suspension
An FDA approved allogeneic pancreatic islet cellular suspension indicated for the treatment of hard to control type 1 diabetes in patients unable to approach target glycemia despite intensive insulin management.
cGMP Pancreatic Islet Manufacturing Facility
State-of-the-art cGMP facility featuring fully certified ISO 7 and ISO 5 processing areas dedicated to the manufacture of high-quality human islets for clinical use.
Autologous Islet Transplant
Isolated autologous islets for the treatment of chronic pancreatitis via partial resection or total pancreatectomy.
Consultation Services
Consultation services covering regulatory, statistical, and trial design for pre-clinical and clinical development of cellular products and biomaterial research.
Morphology Assessment with Islet Scoring
Evaluation of islet morphology based on five categories including size distribution, fragmentation, density, border, and shape using a maximum score of 10.
Clinical-grade allogeneic pancreatic islet cellular suspension
cGMP-manufactured allogeneic pancreatic islet cellular suspension produced for clinical transplantation and regulated clinical use.
Lantidra (donislecel-jujn) Allogeneic Pancreatic Islet Cellular Suspension
An FDA approved allogeneic pancreatic islet cellular suspension indicated for the treatment of hard to control type 1 diabetes in patients unable to approach target glycemia despite intensive insulin management.
cGMP Pancreatic Islet Manufacturing Facility
State-of-the-art cGMP facility featuring fully certified ISO 7 and ISO 5 processing areas dedicated to the manufacture of high-quality human islets for clinical use.
Autologous Islet Transplant
Isolated autologous islets for the treatment of chronic pancreatitis via partial resection or total pancreatectomy.
Consultation Services
Consultation services covering regulatory, statistical, and trial design for pre-clinical and clinical development of cellular products and biomaterial research.
Morphology Assessment with Islet Scoring
Evaluation of islet morphology based on five categories including size distribution, fragmentation, density, border, and shape using a maximum score of 10.
Services
Contract manufacture and isolation of autologous and allogeneic pancreatic islets in a cGMP facility for clinical transplantation and clinical trials.
Preclinical contract research including in vivo transplantation in rodent and non-human primate models, biocompatibility assessment, toxicology studies and development of microencapsulation approaches.
In‑vitro services including multiparametric microfluidic assays, static and dynamic GSIS, oxygen consumption measurements, morphology scoring, viability and purity assessments for islets and cell products.
Consulting services covering IND/IDE enabling experiment planning, clinical study design, statistical analysis planning, regulatory interactions and regulatory document preparation.
Contract manufacture and isolation of autologous and allogeneic pancreatic islets in a cGMP facility for clinical transplantation and clinical trials.
Preclinical contract research including in vivo transplantation in rodent and non-human primate models, biocompatibility assessment, toxicology studies and development of microencapsulation approaches.
In‑vitro services including multiparametric microfluidic assays, static and dynamic GSIS, oxygen consumption measurements, morphology scoring, viability and purity assessments for islets and cell products.
Consulting services covering IND/IDE enabling experiment planning, clinical study design, statistical analysis planning, regulatory interactions and regulatory document preparation.
Expertise Areas
- Islet transplantation and cell therapy development
- cGMP cell manufacturing for clinical applications
- Microfluidic assay and biochip development
- Microencapsulation and biomaterials for immune protection
Key Technologies
- cGMP cleanroom manufacturing (ISO-classified)
- Microfluidic biochips and perifusion systems
- Alginate-based microencapsulation
- Glucose-stimulated insulin secretion (GSIS) assays